|  |  |  |  |
| --- | --- | --- | --- |
| Cell line | Source | Culture conditions | Number of transplants |
| B16F0 | RIKEN BioResource Center（Ibaraki, Japan） | RPMI-1640 containing, Glutamax (Gibco), 10% fetal bovine serum(Serana), and 1% penicillin/streptomycin (Wako). | 1 × 105 cells  |
| B16F10 | RIKEN BioResource Center（Ibaraki, Japan） | RPMI-1640 containing, Glutamax (Gibco), 10% fetal bovine serum (Serana), and 1% penicillin/streptomycin (Wako). | 1 × 106 cells |
| B16F10-OVA | Dr. Yoshihiro Hayakawa (University of Toyama, Japan) | RPMI-1640 containing, Glutamax (Gibco), 10% fetal bovine serum(Serana), and 1% penicillin/streptomycin (Wako). | 1 × 106 cells |
| MB49 | Merck Sigma-Aldrich  | High-glucose DMEM (Wako) containing, Glutamax (Gibco), MEM non-essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), 10% fetal bovine serum (Serana), and 1% penicillin/streptomycin (Wako).  | 2 × 105 cells |
| EO771 | ATCC | High-glucose DMEM (Wako) containing, Glutamax (Gibco), MEM non-essential amino acids (Gibco), 10% fetal bovine serum (Serana), 1% penicillin/streptomycin (Wako) and 20mM HEPES (Gibco). | 1 × 106 cells |
| MC38 | Kerafast (Boston, MA, USA). | High-glucose DMEM (Wako) containing, Glutamax (Gibco), MEM non-essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), 10% fetal bovine serum (Serana), and 1% penicillin/streptomycin (Wako). | 1 × 106 cells |

**Supplementary Table 2.** Cell Lines, sources, culture conditions, and transplant quantities.